37 related articles for article (PubMed ID: 10818600)
1. Impact of circulating tumor DNA in hepatocellular and pancreatic carcinomas.
Dhayat SA; Yang Z
J Cancer Res Clin Oncol; 2020 Jul; 146(7):1625-1645. PubMed ID: 32338295
[TBL] [Abstract][Full Text] [Related]
2. Circulating free tumor DNA in non-small cell lung cancer (NSCLC): clinical application and future perspectives.
Herbreteau G; Vallée A; Charpentier S; Normanno N; Hofman P; Denis MG
J Thorac Dis; 2019 Jan; 11(Suppl 1):S113-S126. PubMed ID: 30775034
[TBL] [Abstract][Full Text] [Related]
3. Colorectal Cancer Liver Metastasis: Evolving Paradigms and Future Directions.
Zarour LR; Anand S; Billingsley KG; Bisson WH; Cercek A; Clarke MF; Coussens LM; Gast CE; Geltzeiler CB; Hansen L; Kelley KA; Lopez CD; Rana SR; Ruhl R; Tsikitis VL; Vaccaro GM; Wong MH; Mayo SC
Cell Mol Gastroenterol Hepatol; 2017 Mar; 3(2):163-173. PubMed ID: 28275683
[TBL] [Abstract][Full Text] [Related]
4. Total DNA input is a crucial determinant of the sensitivity of plasma cell-free DNA EGFR mutation detection using droplet digital PCR.
Zhang Y; Xu Y; Zhong W; Zhao J; Chen M; Zhang L; Li L; Wang M
Oncotarget; 2017 Jan; 8(4):5861-5873. PubMed ID: 28052016
[TBL] [Abstract][Full Text] [Related]
5. [Research Advancement on EGFR Mutation Detection of Cell-free DNA and Tumor Cell in Peripheral Blood of Patients with Non-small Cell Lung Cancer].
Zhang Y; Xu Y; Wang M
Zhongguo Fei Ai Za Zhi; 2016 Nov; 19(11):766-772. PubMed ID: 27866520
[TBL] [Abstract][Full Text] [Related]
6. Blood as a Substitute for Tumor Tissue in Detecting EGFR Mutations for Guiding EGFR TKIs Treatment of Nonsmall Cell Lung Cancer: A Systematic Review and Meta-Analysis.
Mao C; Yuan JQ; Yang ZY; Fu XH; Wu XY; Tang JL
Medicine (Baltimore); 2015 May; 94(21):e775. PubMed ID: 26020382
[TBL] [Abstract][Full Text] [Related]
7. Do circulating tumor cells, exosomes, and circulating tumor nucleic acids have clinical utility? A report of the association for molecular pathology.
Gold B; Cankovic M; Furtado LV; Meier F; Gocke CD
J Mol Diagn; 2015 May; 17(3):209-24. PubMed ID: 25908243
[TBL] [Abstract][Full Text] [Related]
8. Role of quantitative and qualitative characteristics of free circulating DNA in the management of patients with non-small cell lung cancer.
Ulivi P; Silvestrini R
Cell Oncol (Dordr); 2013 Dec; 36(6):439-48. PubMed ID: 24177991
[TBL] [Abstract][Full Text] [Related]
9. The clinical utilization of circulating cell free DNA (CCFDNA) in blood of cancer patients.
Elshimali YI; Khaddour H; Sarkissyan M; Wu Y; Vadgama JV
Int J Mol Sci; 2013 Sep; 14(9):18925-58. PubMed ID: 24065096
[TBL] [Abstract][Full Text] [Related]
10. Cell-free nucleic acids as biomarkers in cancer patients.
Schwarzenbach H; Hoon DS; Pantel K
Nat Rev Cancer; 2011 Jun; 11(6):426-37. PubMed ID: 21562580
[TBL] [Abstract][Full Text] [Related]
11. Methylation patterns in cell-free plasma DNA reflect removal of the primary tumor and drug treatment of breast cancer patients.
Liggett TE; Melnikov AA; Marks JR; Levenson VV
Int J Cancer; 2011 Jan; 128(2):492-9. PubMed ID: 20473856
[TBL] [Abstract][Full Text] [Related]
12. Detecting cell-free circulating hTERT mRNA in the plasma may identify a subset of nonsmall cell lung cancer patients.
Pelosi G; Schianchi E; Dell'orto P; Veronesi G; Spaggiari L; Pasini F; Sozzi G; Brambilla E; Griso C; Viale G
Virchows Arch; 2006 Jan; 448(1):7-15. PubMed ID: 16193293
[TBL] [Abstract][Full Text] [Related]
13. Genetic alterations in bronchial mucosa and plasma DNA from individuals at high risk of lung cancer.
Allan JM; Hardie LJ; Briggs JA; Davidson LA; Watson JP; Pearson SB; Muers MF; Wild CP
Int J Cancer; 2001 Feb; 91(3):359-65. PubMed ID: 11169960
[TBL] [Abstract][Full Text] [Related]
14. Microsatellite alterations and TP53 mutations in plasma DNA of small-cell lung cancer patients: follow-up study and prognostic significance.
Gonzalez R; Silva JM; Sanchez A; Dominguez G; Garcia JM; Chen XQ; Stroun M; Provencio M; España P; Anker P; Bonilla F
Ann Oncol; 2000 Sep; 11(9):1097-104. PubMed ID: 11061602
[TBL] [Abstract][Full Text] [Related]
15. Genetic abnormalities in plasma DNA of patients with lung cancer and other respiratory diseases.
Khan S; Coulson JM; Woll PJ
Int J Cancer; 2004 Jul; 110(6):891-5. PubMed ID: 15170672
[TBL] [Abstract][Full Text] [Related]
16. Cell-free circulating tumor DNA in plasma/serum of non-small cell lung cancer.
Nie K; Jia Y; Zhang X
Tumour Biol; 2015 Jan; 36(1):7-19. PubMed ID: 25352029
[TBL] [Abstract][Full Text] [Related]
17. Molecular genetics of small cell lung carcinoma.
Wistuba II; Gazdar AF; Minna JD
Semin Oncol; 2001 Apr; 28(2 Suppl 4):3-13. PubMed ID: 11479891
[TBL] [Abstract][Full Text] [Related]
18. Detection of microsatellite alterations in the DNA isolated from tumor cells and from plasma DNA of patients with lung cancer.
Bruhn N; Beinert T; Oehm C; Jandrig B; Petersen I; Chen XQ; Possinger K; Fleischhacker M
Ann N Y Acad Sci; 2000 Apr; 906():72-82. PubMed ID: 10818600
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
